Compare CDXS & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CDXS | BWG |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Finance/Investors Services |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.4M | 134.7M |
| IPO Year | 2008 | N/A |
| Metric | CDXS | BWG |
|---|---|---|
| Price | $1.19 | $6.82 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $6.14 | N/A |
| AVG Volume (30 Days) | ★ 813.0K | 110.1K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.37% |
| EPS Growth | ★ 43.82 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $138,590,000.00 | N/A |
| Revenue This Year | $4.97 | N/A |
| Revenue Next Year | $18.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 32.30 | N/A |
| 52 Week Low | $0.96 | $6.69 |
| 52 Week High | $2.98 | $8.68 |
| Indicator | CDXS | BWG |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 35.76 |
| Support Level | $1.12 | $6.76 |
| Resistance Level | $1.24 | $7.05 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 6.52 | 30.27 |
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.